Janus Henderson Group PLC Grows Position in Disc Medicine, Inc. (NASDAQ:IRON)

Janus Henderson Group PLC grew its holdings in Disc Medicine, Inc. (NASDAQ:IRON) by 17.7% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 521,773 shares of the company’s stock after buying an additional 78,595 shares during the period. Janus Henderson Group PLC owned 2.11% of Disc Medicine worth $32,465,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Vanguard Group Inc. raised its holdings in Disc Medicine by 18.9% in the 3rd quarter. Vanguard Group Inc. now owns 665,452 shares of the company’s stock valued at $31,263,000 after acquiring an additional 105,685 shares during the last quarter. SG Americas Securities LLC purchased a new position in Disc Medicine during the fourth quarter worth approximately $528,000. China Universal Asset Management Co. Ltd. acquired a new position in Disc Medicine during the fourth quarter worth $161,000. Bleakley Financial Group LLC purchased a new stake in Disc Medicine in the 4th quarter valued at $215,000. Finally, Simplicity Solutions LLC acquired a new stake in shares of Disc Medicine in the 4th quarter worth $215,000. 83.70% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on IRON. Wedbush reissued an “outperform” rating and set a $57.00 price target (up previously from $43.00) on shares of Disc Medicine in a research report on Friday, June 14th. BMO Capital Markets reissued an “outperform” rating and issued a $70.00 price target (up previously from $50.00) on shares of Disc Medicine in a research note on Monday, June 17th. Raymond James raised their price target on shares of Disc Medicine from $40.00 to $43.00 and gave the stock an “outperform” rating in a report on Friday, May 10th. HC Wainwright reaffirmed a “buy” rating and issued a $70.00 price target on shares of Disc Medicine in a research note on Wednesday, July 10th. Finally, Morgan Stanley cut their price objective on Disc Medicine from $75.00 to $40.00 and set an “equal weight” rating for the company in a research report on Tuesday, April 2nd. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $62.57.

Disc Medicine Price Performance

Shares of IRON stock traded down $0.61 on Wednesday, hitting $42.42. The stock had a trading volume of 38,077 shares, compared to its average volume of 399,383. The company’s 50 day moving average price is $42.18 and its 200-day moving average price is $48.02. Disc Medicine, Inc. has a 1 year low of $25.60 and a 1 year high of $77.60. The firm has a market capitalization of $1.05 billion, a P/E ratio of -12.73 and a beta of 0.57.

Disc Medicine (NASDAQ:IRON) last released its earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.09). On average, equities analysts forecast that Disc Medicine, Inc. will post -4.47 EPS for the current year.

Disc Medicine Company Profile

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.